
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3787189/publications.pdf Version: 2024-02-01



KVIE AMPED

#	Article	IF	CITATIONS
1	Melanoma is associated with an increased risk of bullous pemphigoid: a large population-based longitudinal study. Archives of Dermatological Research, 2022, 314, 77-83.	1.1	6
2	Inhibition of dipeptidyl-peptidase 4 induces upregulation of the late cornified envelope cluster in keratinocytes. Archives of Dermatological Research, 2022, 314, 909-915.	1.1	5
3	Assessing the risk factors for anxiety, depression and postâ€traumatic stress disorder through the International Pemphigus and Pemphigoid Foundation. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	3
4	Gene expression profiling of laminin α3â€blocked keratinocytes reveals an immuneâ€independent mechanism of blistering. Experimental Dermatology, 2022, 31, 615-621.	1.4	5
5	The Immunogenetics of Autoimmune Blistering Diseases. Advances in Experimental Medicine and Biology, 2022, 1367, 173-212.	0.8	0
6	Development of <i>Pneumocystis pneumonia</i> in a patient receiving both rituximab and IVIg for pemphigus vulgaris. JDDG - Journal of the German Society of Dermatology, 2022, 20, 520-521.	0.4	2
7	<i>Pneumocystis</i> â€Pneumonie bei einem Patienten mit Rituximab―und IVIGâ€Therapie gegen Pemphigus vulgaris. JDDG - Journal of the German Society of Dermatology, 2022, 20, 520-522.	0.4	1
8	Direct Immunofluorescence Findings in 145 Consecutive Patients Receiving a Conjunctival Biopsy for Cicatrizing Conjunctivitis. Ocular Immunology and Inflammation, 2021, 29, 1478-1479.	1.0	0
9	The role of Dipeptidyl Peptidaseâ€4 in cutaneous disease. Experimental Dermatology, 2021, 30, 304-318.	1.4	28
10	Hidradenitis suppurativa is associated with acne keloidalis nuchae: a population-based study. Archives of Dermatological Research, 2021, 313, 333-337.	1.1	11
11	â€~Hidradenitis suppurativa and amyloidosis: a possible association with the pyrin inflammasome': reply from authors. Clinical and Experimental Dermatology, 2021, 46, 1118-1119.	0.6	0
12	A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy. Antibodies, 2021, 10, 19.	1.2	6
13	Autoreactive T cells in pemphigus: perpetrator and target. Italian Journal of Dermatology and Venereology, 2021, 156, .	0.1	3
14	Characterizing the proteome of bullous pemphigoid blister fluid utilizing tandem mass tag labeling coupled with LC–MS/MS. Archives of Dermatological Research, 2021, , 1.	1.1	8
15	The risk of Pneumocystis pneumonia in patients ofÂautoimmune blistering disease—reply to letter entitled "Pemphigus management guidelines: A life-saving perspective― Journal of the American Academy of Dermatology, 2021, 85, e289.	0.6	0
16	Eosinophils in bullous pemphigoid. Panminerva Medica, 2021, 63, 368-378.	0.2	9
17	Subunit-Specific Reactivity of Autoantibodies Against Laminin-332 Reveals Direct Inflammatory Mechanisms on Keratinocytes. Frontiers in Immunology, 2021, 12, 775412.	2.2	9
18	Treatment and clinical outcomes in antiâ€p200 pemphigoid: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 465-472.	1.3	9

#	Article	IF	CITATIONS
19	Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review. International Journal of Dermatology, 2020, 59, 520-524.	0.5	7
20	lgA pemphigus: A systematic review. Journal of the American Academy of Dermatology, 2020, 82, 1386-1392.	0.6	45
21	Disease-dependent Risk of Pneumocystis Pneumonia. Chest, 2020, 158, 2704-2705.	0.4	1
22	Patients with pemphigus are at an increased risk of developing rheumatoid arthritis: a large-scale cohort study. Immunologic Research, 2020, 68, 373-378.	1.3	5
23	Pemphigus vulgaris manifesting as severe oral and epiglottal epithelial dysplasia. JDDG - Journal of the German Society of Dermatology, 2020, 18, 895-896.	0.4	0
24	A Review Comparing International Guidelines for the Management of Bullous Pemphigoid, Pemphigoid Gestationis, Mucous Membrane Pemphigoid, and Epidermolysis Bullosa Acquisita. American Journal of Clinical Dermatology, 2020, 21, 557-565.	3.3	32
25	Complete remission on minimal therapy vs. off therapy: for what should we be aiming in pemphigus?. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e404-e405.	1.3	1
26	Hidradenitis suppurativa and pemphigus: a cross-sectional study. Archives of Dermatological Research, 2020, 312, 501-505.	1.1	5
27	Amyloidosis in hidradenitis suppurativa: a crossâ€sectional study and review of the literature. Clinical and Experimental Dermatology, 2020, 45, 565-571.	0.6	8
28	The Role of Collagen XVII in Cancer: Squamous Cell Carcinoma and Beyond. Frontiers in Oncology, 2020, 10, 352.	1.3	33
29	Solar Ultraviolet Exposure in Individuals Who Perform Outdoor Sport Activities. Sports Medicine - Open, 2020, 6, 42.	1.3	22
30	The Risk of Pulmonary Embolism in Patients With Pemphigus: A Population-Based Large-Scale Longitudinal Study. Frontiers in Immunology, 2019, 10, 1559.	2.2	7
31	From bench to bedside: evolving therapeutic targets in autoimmune blistering disease. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2239-2252.	1.3	10
32	Evaluation of serum cytokine and chemokine levels in dermatitis herpetiformis: a systematic review and meta-analysis. Immunologic Research, 2019, 67, 265-266.	1.3	0
33	Long noncoding RNA singleâ€nucleotide polymorphisms: a new cause of genetic susceptibility to autoimmune blistering disease. British Journal of Dermatology, 2019, 181, 241-242.	1.4	0
34	Epidermal expression of eotaxins and thymic stromal lymphopoietin in eosinophil rich dermatoses. Archives of Dermatological Research, 2019, 311, 705-710.	1.1	10
35	Synergy among non-desmoglein antibodies contributes to the immunopathology of desmoglein antibody–negative pemphigus vulgaris. Journal of Biological Chemistry, 2019, 294, 4520-4528.	1.6	40
36	Digital Quantification of Epidermal Protein Expression in Paraffin-Embedded Tissue Using Immunohistochemistry. Methods in Molecular Biology, 2019, 2109, 75-82.	0.4	3

#	Article	IF	CITATIONS
37	<p>Distinguishing truly recalcitrant prurigo nodularis from poor treatment adherence: a response to treatment-resistant prurigo nodularis [Response to letter]</p> . Clinical, Cosmetic and Investigational Dermatology, 2019, Volume 12, 371-372.	0.8	0
38	Gastrointestinal symptoms, gastrointestinal bleeding and the role of diet in patients with autoimmune blistering disease: a survey of the International Pemphigus and Pemphigoid Foundation. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1935-1940.	1.3	6
39	Epidermolysis bullosa acquisita: A comprehensive review. Autoimmunity Reviews, 2019, 18, 786-795.	2.5	55
40	Dapsone, two birds with one stone: a response to "Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients― Journal of the American Academy of Dermatology, 2019, 85, e369.	0.6	3
41	Pemphigus subtype: a confounder in determining the association of oral involvement with postâ€rituximab relapses. Dermatologic Therapy, 2019, 32, e12918.	0.8	3
42	<p>Treatment-resistant prurigo nodularis: challenges and solutions</p> . Clinical, Cosmetic and Investigational Dermatology, 2019, Volume 12, 163-172.	0.8	32
43	Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmunity Reviews, 2019, 18, 526-534.	2.5	63
44	Erythematous papular rash with sparing of folds. JAAD Case Reports, 2019, 5, 135-137.	0.4	0
45	Comment on "Incidence of pneumocystosis among patients exposed to immunosuppression― Journal of the American Academy of Dermatology, 2019, 81, e47.	0.6	1
46	Editorial: Skin Blistering Diseases. Frontiers in Medicine, 2019, 6, 60.	1.2	1
47	Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2018, 16, 196-198.	0.4	14
48	Paraneoplastic autoimmune multi-organ syndrome is a distinct entity from traditional pemphigus subtypes. Nature Reviews Disease Primers, 2018, 4, 18012.	18.1	15
49	Lokalisiertes präbiales bullöses Pemphigoid bei einer Patientin unter Pembrolizumabâ€Therapie wegen eines metastasierten Melanoms. JDDG - Journal of the German Society of Dermatology, 2018, 16, 196-198.	0.4	5
50	Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center. Journal of the American Academy of Dermatology, 2018, 78, 806-808.	0.6	32
51	Role of Intravenous Immunoglobulin in Dermatologic Disorders. , 2018, , 401-423.		3
52	Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis. American Journal of Clinical Dermatology, 2018, 19, 479-487.	3.3	58
53	A case of photodistributed multicentric reticulohistiocytosis: correlation with multiphoton microscopy imaging. JDDG - Journal of the German Society of Dermatology, 2018, 16, 781-783.	0.4	0
54	Current practices for the prophylaxis against bone mineral density loss in patients with autoimmune blistering disease treated with corticosteroids: an expert survey. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e416-e418.	1.3	3

#	Article	IF	CITATIONS
55	Second primary cutaneous Tâ€cell lymphoma in patients with nonâ€Hodgkin lymphoma: a chickenâ€orâ€theâ€e issue. International Journal of Dermatology, 2018, 57, 113-113.	2gg _{0.5}	0
56	Pemphigus vulgaris complicated by extensive keloid scarring. Clinical and Experimental Dermatology, 2018, 43, 76-77.	0.6	2
57	Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management. Clinical Reviews in Allergy and Immunology, 2018, 54, 26-51.	2.9	158
58	Targeted Therapies for Autoimmune Bullous Diseases: Current Status. Drugs, 2018, 78, 1527-1548.	4.9	74
59	Mechanisms of pathogenic effects of eosinophil cationic protein and eosinophilâ€derived neurotoxin on human keratinocytes. Experimental Dermatology, 2018, 27, 1322-1327.	1.4	27
60	Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study. Immunologic Research, 2018, 66, 425-430.	1.3	36
61	The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease. Frontiers in Medicine, 2018, 5, 201.	1.2	92
62	Non-Desmoglein Antibodies in Patients With Pemphigus Vulgaris. Frontiers in Immunology, 2018, 9, 1190.	2.2	86
63	Multizentrische Retikulohistiozytose in lichtexponierten Arealen: Korrelation mit Multiphotonenmikroskopie-Bildgebung. JDDG - Journal of the German Society of Dermatology, 2018, 16, 781-783.	0.4	0
64	Paraneoplastic autoimmune multiorgan syndrome (PAMS): Beyond the single phenotype of paraneoplastic pemphigus. Autoimmunity Reviews, 2018, 17, 1002-1010.	2.5	60
65	Gastrointestinal prophylaxis in patients with autoimmune blistering disease treated with corticosteroids: an expert survey. International Journal of Dermatology, 2018, 57, e125-e126.	0.5	3
66	A multiâ€hit hypothesis of bullous pemphigoid and associated neurological disease: Is <i><scp>HLAâ€DQB1</scp>*03:01</i> , a potential link between immune privileged antigen exposure and epitope spreading?. Hla, 2017, 89, 127-134.	0.4	38
67	615 Eosinophil major basic protein has a concentration-dependent cytotoxic effect on cultured keratinocytes. Journal of Investigative Dermatology, 2017, 137, S106.	0.3	3
68	Vesiculobullous eruption in a patient receiving psoralen ultraviolet A (PUVA) treatment for prurigo nodules: a case of PUVA-aggravated pemphigoid nodularis. Clinical and Experimental Dermatology, 2017, 42, 833-835.	0.6	9
69	Determining the Incidence of <i>Pneumocystis</i> Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis. JAMA Dermatology, 2017, 153, 1137.	2.0	43
70	A case report of bullous pemphigoid associated with a melanoma and review of the literature. Melanoma Research, 2017, 27, 65-67.	0.6	10
71	Coverage of Intravenous Immunoglobulin for Autoimmune Blistering Diseases Among US Insurers. JAMA Dermatology, 2017, 153, 1189.	2.0	3
72	Balancing the risks and benefits of prophylaxis: a reply to "Pneumocystis jirovecipneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditionsâ€: International Journal of Dermatology, 2017, 56, e4-e5.	0.5	5

#	Article	IF	CITATIONS
73	Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials. Anais Brasileiros De Dermatologia, 2017, 92, 139-141.	0.5	29
74	Therapy of Immunobullous Disorders. , 2017, , 767-774.		0
75	Thrombotic thrombocytopenic purpura in a postoperative patient taking cephalexin responding to plasmapheresis: A case report and review of cephalosporinâ€induced <scp>TTP</scp> . Journal of Clinical Apheresis, 2016, 31, 473-475.	0.7	4
76	Reply to: Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. British Journal of Dermatology, 2016, 174, 461-461.	1.4	4
77	A systematic review with pooled analysis of clinical presentation and immunodiagnostic testing in mucous membrane pemphigoid: association of antiâ€lamininâ€332 IgG with oropharyngeal involvement and the usefulness of <scp>ELISA</scp> . Journal of the European Academy of Dermatology and Venereology. 2016. 30. 72-77.	1.3	38
78	Granulomatosis with polyangiitis (GPA) initially presenting as sigmoiditis with the later development of spontaneous subcapsular hematoma. International Journal of Colorectal Disease, 2016, 31, 1365-1366.	1.0	1
79	Is anti-BP180 IgE associated with clinical phenotype? A reply to â€~Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid'. Archives of Dermatological Research, 2016, 308, 65-66.	1.1	1
80	Immune response in pemphigus and beyond: progresses and emerging concepts. Seminars in Immunopathology, 2016, 38, 57-74.	2.8	68
81	Association of Google Search Volume Index Peaks for Skin Cancer With Skin Cancer Awareness Month—Reply. JAMA Dermatology, 2016, 152, 113.	2.0	5
82	Second Primary Malignancies in CTCL Patients from 1992 to 2011: A SEER-Based, Population-Based Study Evaluating Time from CTCL Diagnosis, Age, Sex, Stage, and CD30+ Subtype. American Journal of Clinical Dermatology, 2016, 17, 71-77.	3.3	41
83	An increased risk of nonâ€ <scp>H</scp> odgkin lymphoma and chronic lymphocytic leukemia in <scp>US</scp> patients with <scp>M</scp> erkel cell carcinoma versus <scp>A</scp> ustralian patients: A clinical clue to a different mechanism of pathogenesis?. Australasian Journal of Dermatology, 2016, 57, e114-6.	0.4	9
84	<scp>TNF</scp> â€i±: a treatment target or cause of sarcoidosis?. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2104-2111.	1.3	67
85	Assessing the prevalence of autoimmune, endocrine, gynecologic, and psychiatric comorbidities in an ethnically diverse cohort of female fibromyalgia patients: does the time from hysterectomy provide a clue?. Journal of Pain Research, 2015, 8, 561.	0.8	7
86	A Review of the Use of Topical Calendula in the Prevention and Treatment of Radiotherapy-Induced Skin Reactions. Antioxidants, 2015, 4, 293-303.	2.2	37
87	A Systematic Review of Patients with Mucocutaneous and Respiratory Complications in Paraneoplastic Autoimmune Multiorgan Syndrome: Castleman's Disease is the Predominant Malignancy. Lung, 2015, 193, 593-596.	1.4	27
88	Private and public coverage policies for rituximab in the treatment of immunobullous disease in the United States. Journal of the American Academy of Dermatology, 2015, 73, 337-338.	0.6	1
89	Visual identification of skin cancer in beachgoers: a need for improved education on nonâ€melanoma skin cancer in the general population and melanoma in the Africanâ€American population. International Journal of Dermatology, 2015, 54, e85-7.	0.5	4
90	Topical antioxidants in radiodermatitis: a clinical review. International Journal of Palliative Nursing, 2015, 21, 446-452.	0.2	19

#	Article	IF	CITATIONS
91	Considerations for the utilization of â€~comparative analysis of colorimetric staining in skin using open-source software' in an experimental setting. Experimental Dermatology, 2015, 24, 717-718.	1.4	3
92	Google Search Trends and Skin Cancer. JAMA Dermatology, 2015, 151, 903.	2.0	69
93	Comparative outcome studies of clinical decision support software: limitations to the practice of evidence-based system acquisition. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, e13-e20.	2.2	2
94	An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 777-782.	1.3	51
95	Bullous Diseases: Old Blisters with New Therapeutic Targets. , 2015, , 135-146.		Ο
96	Assessing the Perceptions of Fibromyalgia Syndrome in United States Among Academic Physicians and Medical Students: Where are We and Where are We Headed?. Journal of Musculoskeletal Pain, 2014, 22, 13-19.	0.3	6
97	Blue skin. International Journal of Dermatology, 2014, 53, 275-276.	0.5	6
98	If Students Cannot Deliver Bad News, They Should Not Be the First to See Patients Awaiting Bad News. Academic Medicine, 2014, 89, 9.	0.8	6
99	Assessing the Current Market of Sunscreen: A Cross-Sectional Study of Sunscreen Availability in Three Metropolitan Counties in the United States. Journal of Skin Cancer, 2014, 2014, 1-7.	0.5	4
100	Conflict of interest in online point-of-care clinical support websites: TableÂ1. Journal of Medical Ethics, 2014, 40, 578-580.	1.0	19
101	Does Improved Confidence in a Disease Relate to Increased Knowledge? Our Experience with Medical Students: Table 1. Pain Medicine, 2014, 15, 483-484.	0.9	5
102	Comparing the accuracy of ultrasound versus fluoroscopy in glenohumeral injections: A systematic review and meta-analysis. Journal of Clinical Ultrasound, 2014, 42, 411-416.	0.4	40
103	The Use of Antioxidants in Radiotherapy-Induced Skin Toxicity. Integrative Cancer Therapies, 2014, 13, 38-45.	0.8	32
104	Injection therapy for the management of superficial subcutaneous lipomas. Journal of Clinical and Aesthetic Dermatology, 2014, 7, 46-8.	0.1	3
105	Pharmaceutical Ethics and Physician Liability in Side Effects. Journal of Medical Humanities, 2013, 34, 497-503.	0.3	1
106	The Merkel Cell Polyomavirus and Its Involvement in Merkel Cell Carcinoma. Dermatologic Surgery, 2013, 39, 232-238.	0.4	44
107	Autoreactive <scp>T</scp> cells in the immune pathogenesis of pemphigus vulgaris. Experimental Dermatology, 2013, 22, 699-704.	1.4	47
108	A schwannoma of the greater petrosal nerve located within the petrous apex and treated with stereotactic radiotherapy. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2013, 34, 596-599.	0.6	7

#	Article	IF	CITATIONS
109	Artist's Statement. Academic Medicine, 2013, 88, 1080.	0.8	0
110	Direct to consumer advertising's effect on medical students: The case of fibromyalgia. Medical Teacher, 2013, 35, 969-970.	1.0	3
111	Complete Spontaneous Regression of Merkel Cell Carcinoma. Global Advances in Health and Medicine, 2013, 2, 7-8.	0.7	1
112	Prophylactic valacyclovir in a patient with recurrent vestibular disturbances secondary to vestibular neuritis. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2012, 33, 487-488.	0.6	6
113	Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. Frontiers in Medicine, 0, 9, .	1.2	51
114	Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms. Frontiers in Immunology, 0, 13, .	2.2	14